Trade Name Review May Shift To Firms, But FDA Unclear Which Tests To Use
Executive Summary
FDA is asking firms to use computerized methods and algorithms that can detect product name similarities as part of a pilot designed to expedite name review. The program, under which companies would generate their own data and submit it to FDA for review, will be discussed at a June 5-6 public meeting